deltatrials
Unknown OBSERVATIONAL NCT04776265

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Real World Evidence of Brentuximab Vedotin Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant

Sponsor: Grupo Argentino de Tratamiento de la Leucemia Aguda

Conditions Hodgkin Lymphoma, Adult Refractory Hodgkin Lymphoma Relapsed Hodgkin's Disease, Adult
Interventions Evaluation of therapeutical approach after ASCT
Updated 9 times since 2021 Last updated: Jan 8, 2024 Started: Jun 1, 2021 Primary completion: Mar 1, 2024 Completion: Apr 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Hodgkin Lymphoma, Adult and Refractory Hodgkin Lymphoma, this trial is ongoing. The trial is conducted by Grupo Argentino de Tratamiento de la Leucemia Aguda and has accumulated 9 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshotNot Yet Recruiting~Nov 2021 – ~Feb 2023 · 15 months · monthly snapshotRecruiting~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

9 versions recorded

  1. Feb 2026 — Present [monthly]

    Unknown

    Status: Recruiting → Unknown

  2. Sep 2025 — Feb 2026 [monthly]

    Recruiting

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting

▶ Show 4 earlier versions

  1. Feb 2023 — Feb 2024 [monthly]

    Recruiting

  2. Nov 2021 — Feb 2023 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  3. May 2021 — Nov 2021 [monthly]

    Not Yet Recruiting

  4. Mar 2021 — May 2021 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grupo Argentino de Tratamiento de la Leucemia Aguda
  • Takeda
Data source: Grupo Argentino de Tratamiento de la Leucemia Aguda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations